VTv Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . vTv Therapeutics
VTVT Stock  USD 15.51  0.09  0.58%   
VTv Therapeutics financial statements provide useful quarterly and yearly information to potential vTv Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on VTv Therapeutics financial statements helps investors assess VTv Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting VTv Therapeutics' valuation are summarized below:
Gross Profit
-9.9 M
Market Capitalization
40.3 M
Enterprise Value Revenue
5.3125
Revenue
1000 K
Earnings Share
(4.37)
There are currently one hundred twenty fundamental trend indicators for vTv Therapeutics that can be evaluated and compared over time across competition. All traders should double-check VTv Therapeutics' current fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 22.8 M in 2024. Enterprise Value is likely to drop to about 14.3 M in 2024

VTv Therapeutics Total Revenue

8,550

Check VTv Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among VTv Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 85.5 K, Interest Expense of 12.3 K or Selling General Administrative of 11.5 M, as well as many indicators such as Price To Sales Ratio of 27.56, Dividend Yield of 0.0 or Days Sales Outstanding of 2 K. VTv financial statements analysis is a perfect complement when working with VTv Therapeutics Valuation or Volatility modules.
  
Check out the analysis of VTv Therapeutics Correlation against competitors.
For more information on how to buy VTv Stock please use our How to Invest in VTv Therapeutics guide.

VTv Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets10.5 M11 M24.1 M
Very volatile
Short and Long Term Debt Total502.6 K529 K30.2 M
Slightly volatile
Other Current Liabilities5.7 M6 M4.5 M
Slightly volatile
Total Current Liabilities15 M10.6 M32.2 M
Slightly volatile
Other Liabilities18.3 M17.4 M7 M
Slightly volatile
Property Plant And Equipment Net342.9 K361 K2.1 M
Slightly volatile
Current Deferred Revenue14.5 K15.3 K949.1 K
Very volatile
Accounts Payable4.8 M4.1 M5.6 M
Pretty Stable
Cash14.4 M9.4 M14.4 M
Very volatile
Non Current Assets Total342.9 K361 K7.4 M
Slightly volatile
Other Assets8.7 M8.3 M3.5 M
Slightly volatile
Cash And Short Term Investments14.4 M9.4 M14.4 M
Very volatile
Common Stock Shares Outstanding1.9 M2.1 M1.9 M
Very volatile
Liabilities And Stockholders Equity10.5 M11 M24.1 M
Very volatile
Non Current Liabilities Total18 M18.9 M145.7 M
Slightly volatile
Other Current Assets1.1 M1.1 M1 M
Slightly volatile
Total Liabilities28.1 M29.6 M177.6 M
Slightly volatile
Property Plant And Equipment Gross1.1 M848 K2.2 M
Slightly volatile
Preferred Stock Total Equity198.4 K208.8 K90.5 M
Slightly volatile
Total Current Assets16.9 M10.7 M17.1 M
Very volatile
Short Term Debt502.6 K529 K23.9 M
Slightly volatile
Property Plant Equipment177 K186.3 K2.1 M
Slightly volatile
Short and Long Term Debt181.4 K191 K2.9 M
Very volatile
Warrants14.2 M14.9 M96.6 M
Slightly volatile
Common Stock Total Equity1.3 M1.2 M587.4 K
Slightly volatile
Capital Surpluse183.4 M291.8 M165.6 M
Slightly volatile
Non Current Liabilities Other23.4 M22.3 M6.1 M
Slightly volatile
Common Stock25.6 K27 K432.1 K
Pretty Stable
Long Term Debt Total8.7 M5.7 M9.3 M
Slightly volatile
Capital Stock25.6 K27 K488.6 K
Very volatile
Capital Lease Obligations524.5 K338 K818.1 K
Slightly volatile

VTv Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization85.5 K90 K458.6 K
Slightly volatile
Interest Expense12.3 K13 K4.3 M
Slightly volatile
Selling General Administrative11.5 M11.9 M10.7 M
Very volatile
Total Revenue8.6 K9 K2.3 M
Pretty Stable
Other Operating Expenses26.4 M25.5 M33.3 M
Slightly volatile
Research Development18 M13.6 M22.8 M
Slightly volatile
Cost Of Revenue16.2 M13.6 M21 M
Slightly volatile
Total Operating Expenses11.3 M11.9 M31.4 M
Slightly volatile
Interest Income562.8 K536 K812.8 K
Slightly volatile
Reconciled Depreciation93.6 K90 K152.8 K
Slightly volatile

VTv Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation1.6 M1.6 M2.1 M
Slightly volatile
Begin Period Cash Flow14.4 M12.1 M14.6 M
Very volatile
Other Cashflows From Financing Activities4.2 M4.4 M19 M
Slightly volatile
Depreciation85.5 K90 K458.6 K
Slightly volatile
Total Cash From Financing Activities23.8 M12 M31.6 M
Slightly volatile
End Period Cash Flow15 M9.4 M14.9 M
Very volatile
Other Cashflows From Investing Activities376.7 K358.8 K156.7 K
Slightly volatile
Issuance Of Capital Stock16.4 M12 M20.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio27.5629.0162.6049
Slightly volatile
Days Sales Outstanding2 K2.6 K1.8 K
Pretty Stable
Stock Based Compensation To Revenue0.690.722.3682
Slightly volatile
Capex To Depreciation0.30.210.3028
Pretty Stable
ROIC0.561.04860.5884
Slightly volatile
Inventory Turnover6.77.05129
Slightly volatile
Days Of Inventory On Hand65.553.5641.7651
Slightly volatile
Payables Turnover3.173.33626.3119
Slightly volatile
Sales General And Administrative To Revenue11.596.9510.5914
Pretty Stable
Research And Ddevelopement To Revenue6.697.0427.5952
Pretty Stable
Capex To Revenue0.01140.0120.0918
Slightly volatile
Cash Per Share4.34.530550.6361
Pretty Stable
Days Payables Outstanding1041091.2 K
Slightly volatile
Income Quality0.770.94230.9279
Pretty Stable
ROE0.470.82050.4963
Slightly volatile
Current Ratio0.951.00361.7357
Very volatile
Receivables Turnover0.140.1583.3457
Pretty Stable
Graham Number48.3250.85991.2 K
Slightly volatile
Capex Per Share0.0120.01260.33
Slightly volatile
Revenue Per Share1.151.215.8558
Very volatile
Interest Debt Per Share0.170.1789152
Slightly volatile
Debt To Assets0.0310.03271.8654
Slightly volatile
Days Of Payables Outstanding1041091.2 K
Slightly volatile
Ebt Per Ebit1.21.01821.1486
Slightly volatile
Quick Ratio0.951.00361.7289
Very volatile
Net Income Per E B T0.540.77990.6648
Pretty Stable
Cash Ratio0.850.88951.5064
Very volatile
Days Of Inventory Outstanding65.553.5641.7651
Slightly volatile
Days Of Sales Outstanding2 K2.6 K1.8 K
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.11.151.0188
Slightly volatile
Fixed Asset Turnover3.13.2713.8799
Very volatile
Debt Ratio0.0310.03271.8654
Slightly volatile
Price Sales Ratio27.5629.0162.6049
Slightly volatile
Asset Turnover0.05190.05460.1939
Pretty Stable
Return On Equity0.470.82050.4963
Slightly volatile
Operating Cycle2 K2.7 K1.9 K
Pretty Stable

VTv Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap22.8 M24 M70.8 M
Slightly volatile

VTv Fundamental Market Drivers

Cash And Short Term Investments9.4 M

VTv Upcoming Events

4th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About VTv Therapeutics Financial Statements

VTv Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although VTv Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in VTv Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on VTv Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue15.3 K14.5 K
Total Revenue9 K8.6 K
Cost Of Revenue13.6 M16.2 M
Stock Based Compensation To Revenue 0.72  0.69 
Sales General And Administrative To Revenue 6.95  11.59 
Research And Ddevelopement To Revenue 7.04  6.69 
Capex To Revenue 0.01  0.01 
Revenue Per Share 1.21  1.15 
Ebit Per Revenue(10.05)(10.56)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for VTv Stock Analysis

When running VTv Therapeutics' price analysis, check to measure VTv Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VTv Therapeutics is operating at the current time. Most of VTv Therapeutics' value examination focuses on studying past and present price action to predict the probability of VTv Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VTv Therapeutics' price. Additionally, you may evaluate how the addition of VTv Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY